SI3600270T1 - Spojine in sestavki za zdravljenje hematoloških motenj - Google Patents
Spojine in sestavki za zdravljenje hematoloških motenjInfo
- Publication number
- SI3600270T1 SI3600270T1 SI201830946T SI201830946T SI3600270T1 SI 3600270 T1 SI3600270 T1 SI 3600270T1 SI 201830946 T SI201830946 T SI 201830946T SI 201830946 T SI201830946 T SI 201830946T SI 3600270 T1 SI3600270 T1 SI 3600270T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compositions
- compounds
- hematological disorders
- treating hematological
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000014951 hematologic disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741011785 | 2017-03-31 | ||
EP18777745.3A EP3600270B1 (en) | 2017-03-31 | 2018-03-30 | Compounds and compositions for treating hematological disorders |
PCT/IB2018/052232 WO2018178947A2 (en) | 2017-03-31 | 2018-03-30 | Compounds and compositions for treating hematological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3600270T1 true SI3600270T1 (sl) | 2023-10-30 |
Family
ID=63677680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201830946T SI3600270T1 (sl) | 2017-03-31 | 2018-03-30 | Spojine in sestavki za zdravljenje hematoloških motenj |
Country Status (24)
Country | Link |
---|---|
US (2) | US11419875B2 (sl) |
EP (2) | EP4252853A3 (sl) |
JP (2) | JP7333136B2 (sl) |
KR (2) | KR102633530B1 (sl) |
CN (1) | CN110691589A (sl) |
AU (2) | AU2018242623B2 (sl) |
BR (1) | BR112019018991A2 (sl) |
CA (1) | CA3056893A1 (sl) |
DK (1) | DK3600270T3 (sl) |
EA (1) | EA201992322A3 (sl) |
ES (1) | ES2950764T3 (sl) |
FI (1) | FI3600270T3 (sl) |
HR (1) | HRP20230657T8 (sl) |
HU (1) | HUE062648T2 (sl) |
IL (3) | IL269536B (sl) |
LT (1) | LT3600270T (sl) |
MX (2) | MX2019011158A (sl) |
PH (1) | PH12019502138A1 (sl) |
PL (1) | PL3600270T3 (sl) |
PT (1) | PT3600270T (sl) |
RS (1) | RS64411B1 (sl) |
SG (1) | SG11201908171TA (sl) |
SI (1) | SI3600270T1 (sl) |
WO (1) | WO2018178947A2 (sl) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA038748B1 (ru) | 2014-01-13 | 2021-10-14 | Ориджин Дискавери Текнолоджиз Лимитед | Способ получения бициклических гетероциклических производных |
MX2019011158A (es) | 2017-03-31 | 2019-10-17 | Aurigene Discovery Tech Ltd | Compuestos y composiciones para tratar trastornos hematologicos. |
WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
WO2021004533A1 (zh) * | 2019-07-10 | 2021-01-14 | 南京明德新药研发有限公司 | 作为irak4和btk多靶点抑制剂的噁唑类化合物 |
WO2021047677A1 (zh) * | 2019-09-12 | 2021-03-18 | 中国科学院上海药物研究所 | 一类irak4激酶抑制剂及其制备和应用 |
PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
BR112022019987A2 (pt) | 2020-04-07 | 2022-11-22 | Bayer Ag | Tiazolpiridinas substituídas, seus sais e uso dos mesmos como substâncias herbicidamente ativas |
US20230310444A1 (en) * | 2020-08-03 | 2023-10-05 | Curis, Inc. | Compositions and methods for treating diseases and disorders |
MX2023005591A (es) * | 2020-11-18 | 2023-05-29 | Curis Inc | Metodos de tratamiento de enfermedades y trastornos. |
WO2022135338A1 (zh) * | 2020-12-25 | 2022-06-30 | 南京明德新药研发有限公司 | 酰胺噁唑类化合物 |
KR20240004476A (ko) * | 2021-04-08 | 2024-01-11 | 쿠리스 인코퍼레이션 | 암 치료를 위한 병용 요법 |
CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
WO2023088435A1 (zh) * | 2021-11-19 | 2023-05-25 | 成都奥睿药业有限公司 | 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用 |
WO2023116866A1 (zh) * | 2021-12-23 | 2023-06-29 | 杭州多域生物技术有限公司 | 一种五元并六元化合物、制备方法、药物组合物和应用 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
DE59010701D1 (de) | 1990-05-18 | 1997-05-22 | Hoechst Ag | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
ES2302881T3 (es) | 1997-07-29 | 2008-08-01 | Alcon Laboratories, Inc. | Composiciones oftalmicas que contienen polimeros de galactomanana y borato. |
AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
GEP20074236B (en) | 2003-05-01 | 2007-11-12 | Bristol Myers Squibb Co | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
WO2004103954A1 (ja) | 2003-05-20 | 2004-12-02 | Ajinomoto Co., Inc. | アミド誘導体 |
WO2004108133A2 (en) | 2003-06-05 | 2004-12-16 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
CA2541299A1 (en) | 2003-10-07 | 2005-04-14 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
CA2563941C (en) | 2004-04-22 | 2014-10-07 | Bayer Cropscience Lp | Method and composition for controlling weeds with a combination of a preemergent, a post emergent and a three-way broadleaf herbicidal compositions |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
WO2006053227A2 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
MX2007007227A (es) | 2004-12-17 | 2007-08-21 | Lilly Co Eli | Derivados de tiazolopiridinona como antagonistas del receptor mch. |
MX2007007226A (es) * | 2004-12-17 | 2007-08-21 | Lilly Co Eli | Antagonistas receptores novedosos de hormona concentradora de melanina (mch). |
EP1674467A1 (en) | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
US7820821B2 (en) | 2006-02-10 | 2010-10-26 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
JP5255559B2 (ja) | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
WO2007121154A2 (en) | 2006-04-11 | 2007-10-25 | Janssen Pharmaceutica, N.V. | Substituted benzothiazole kinase inhibitors |
WO2008030579A2 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
CN101616910A (zh) | 2006-09-07 | 2009-12-30 | 比奥根艾迪克Ma公司 | 作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物 |
WO2008061109A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
WO2008073825A1 (en) | 2006-12-08 | 2008-06-19 | Exelixis, Inc. | Lxr and fxr modulators |
JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
CA2690557A1 (en) * | 2007-06-14 | 2008-12-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
CA2690619A1 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
EA201070238A1 (ru) | 2007-08-08 | 2010-08-30 | Мерк Сероно С.А. | Соединения пиримидина |
EP2252617A1 (en) | 2008-02-13 | 2010-11-24 | CGI Pharmaceuticals, Inc. | 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof |
EP2311842A3 (en) * | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
US8716312B2 (en) | 2008-11-19 | 2014-05-06 | Merck Sharp & Dohme Corporation | Inhibitors of diacylglycerol acyltransferase |
WO2010071819A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
SG172382A1 (en) | 2008-12-23 | 2011-07-28 | Hoffmann La Roche | Dihydropyridone ureas as p2x7 modulators |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
US20130035326A1 (en) * | 2009-08-19 | 2013-02-07 | Ambit Biosciences Corporation | Biaryl compounds and methods of use thereof |
CA2777565C (en) | 2009-10-13 | 2019-06-18 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic diphenylamine small molecule compounds and their uses |
AU2011242711C1 (en) | 2010-04-22 | 2016-04-21 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
JP2013525453A (ja) | 2010-04-30 | 2013-06-20 | メルク・シャープ・エンド・ドーム・コーポレイション | ホスホイノシチド依存性キナーゼ1(pdk1)阻害薬 |
WO2011163640A1 (en) | 2010-06-24 | 2011-12-29 | Chemocentryx, Inc. | C5ar antagonists |
JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体 |
EP2640708A1 (en) | 2010-11-19 | 2013-09-25 | Ligand Pharmaceuticals Inc. | Heterocycle amines and uses thereof |
SI2655357T1 (sl) | 2010-12-20 | 2016-10-28 | Merck Serono S.A. | Derivati indazolil triazola kot zaviralci IRAK |
AU2012242926B2 (en) | 2011-04-12 | 2016-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria |
WO2013042137A1 (en) * | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
PT2766359T (pt) * | 2011-10-14 | 2016-07-14 | Ambit Biosciences Corp | Compostos heterocíclicos e utilização dos mesmos como moduladores de recetores tirosina-cinase de tipo iii |
EP2768509B1 (en) | 2011-10-20 | 2017-03-22 | Glaxosmithkline LLC | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
KR101385603B1 (ko) | 2012-05-17 | 2014-04-21 | 한국원자력의학원 | 벤조티아졸 유도체 및 암 치료를 위한 그의 용도 |
WO2014003483A1 (en) | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
US9334249B2 (en) | 2012-11-03 | 2016-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
EP2999470B1 (en) | 2013-05-22 | 2017-08-16 | Children's Hospital Medical Center | Combination therapy for mds |
TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
KR20160115933A (ko) | 2014-01-10 | 2016-10-06 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak4 억제제로서의 인다졸 화합물 |
EA038748B1 (ru) * | 2014-01-13 | 2021-10-14 | Ориджин Дискавери Текнолоджиз Лимитед | Способ получения бициклических гетероциклических производных |
SG11201606367YA (en) | 2014-02-06 | 2016-09-29 | Abbvie Inc | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
EP3157521A4 (en) | 2014-06-20 | 2018-02-14 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as irak4 inhibitors |
JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
CU20180006A7 (es) | 2015-07-15 | 2018-06-05 | Aurigene Discovery Tech Ltd | Compuestos de indazaol y azaindazol como inhibidores de irak-4 |
BR112018000635A2 (pt) | 2015-07-15 | 2018-09-18 | Aurigene Discovery Tech Ltd | compostos aza substituídos como inibidores irak-4 |
US10065946B2 (en) * | 2015-08-04 | 2018-09-04 | Rigel Pharmaceuticals, Inc. | Benzazole compounds and methods for making and using the compounds |
US20210292843A1 (en) | 2016-10-28 | 2021-09-23 | Children's Hospital Medical Center | Treatment of diseases associated with activated irak |
MX2019011158A (es) | 2017-03-31 | 2019-10-17 | Aurigene Discovery Tech Ltd | Compuestos y composiciones para tratar trastornos hematologicos. |
BR112020008214A2 (pt) | 2017-10-31 | 2020-10-27 | Curis, Inc. | compostos e composições para tratar distúrbios hematológicos |
-
2018
- 2018-03-30 MX MX2019011158A patent/MX2019011158A/es unknown
- 2018-03-30 PT PT187777453T patent/PT3600270T/pt unknown
- 2018-03-30 JP JP2019552983A patent/JP7333136B2/ja active Active
- 2018-03-30 CN CN201880022870.5A patent/CN110691589A/zh active Pending
- 2018-03-30 EA EA201992322A patent/EA201992322A3/ru unknown
- 2018-03-30 IL IL269536A patent/IL269536B/en unknown
- 2018-03-30 KR KR1020197032104A patent/KR102633530B1/ko active IP Right Grant
- 2018-03-30 LT LTEPPCT/IB2018/052232T patent/LT3600270T/lt unknown
- 2018-03-30 SI SI201830946T patent/SI3600270T1/sl unknown
- 2018-03-30 EP EP23173240.5A patent/EP4252853A3/en active Pending
- 2018-03-30 HR HRP20230657TT patent/HRP20230657T8/hr unknown
- 2018-03-30 HU HUE18777745A patent/HUE062648T2/hu unknown
- 2018-03-30 KR KR1020247003678A patent/KR20240019391A/ko active Application Filing
- 2018-03-30 FI FIEP18777745.3T patent/FI3600270T3/fi active
- 2018-03-30 US US16/498,866 patent/US11419875B2/en active Active
- 2018-03-30 WO PCT/IB2018/052232 patent/WO2018178947A2/en active Application Filing
- 2018-03-30 RS RS20230544A patent/RS64411B1/sr unknown
- 2018-03-30 SG SG11201908171T patent/SG11201908171TA/en unknown
- 2018-03-30 EP EP18777745.3A patent/EP3600270B1/en active Active
- 2018-03-30 CA CA3056893A patent/CA3056893A1/en active Pending
- 2018-03-30 PL PL18777745.3T patent/PL3600270T3/pl unknown
- 2018-03-30 IL IL293783A patent/IL293783B2/en unknown
- 2018-03-30 DK DK18777745.3T patent/DK3600270T3/da active
- 2018-03-30 BR BR112019018991A patent/BR112019018991A2/pt unknown
- 2018-03-30 ES ES18777745T patent/ES2950764T3/es active Active
- 2018-03-30 IL IL305150A patent/IL305150B1/en unknown
- 2018-03-30 AU AU2018242623A patent/AU2018242623B2/en active Active
-
2019
- 2019-09-18 PH PH12019502138A patent/PH12019502138A1/en unknown
- 2019-09-19 MX MX2022001343A patent/MX2022001343A/es unknown
-
2022
- 2022-06-29 US US17/853,299 patent/US20220339161A1/en active Pending
-
2023
- 2023-08-09 JP JP2023129903A patent/JP2023154005A/ja not_active Withdrawn
-
2024
- 2024-06-11 AU AU2024203943A patent/AU2024203943A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL293783A (en) | Compounds and preparations for the treatment of hematological disorders | |
IL274248A (en) | Compounds and preparations for the treatment of hematological disorders | |
IL291533A (en) | Compounds and preparations including them for the treatment of diseases of the central nervous system | |
HK1259453A1 (zh) | 可用於治療與ntrk相關的病症的化合物和組合物 | |
HK1255330A1 (zh) | 適用於治療與ntrk相關的病症的化合物和組合物 | |
HK1252741A1 (zh) | 用於治療神經疾病的組合物和方法 | |
IL275506A (en) | Preparations and methods for the treatment of central nervous system disorders | |
IL275562A (en) | Preparations and methods for the treatment of central nervous system disorders | |
PT3250210T (pt) | Composições e métodos para o tratamento de distúrbios do snc | |
HK1258696A1 (zh) | 治療或預防皮膚障礙的新型組合物和方法 | |
EP3280420A4 (en) | Compositions and methods for treating cns disorders | |
IL272061A (en) | Preparations for the treatment of stress-related disorders | |
HK1256298A1 (zh) | 用於治療和預防神經退化性病症的組合物和方法 | |
EP3262065C0 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES | |
EP3322406A4 (en) | TRANSPARENT METHODS AND COMPOSITIONS FOR THE TREATMENT OF MAMMARY DISEASES | |
IL265255A (en) | Dementia treatment preparations |